423 related articles for article (PubMed ID: 30123221)
1. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
Vo MC; Nguyen-Pham TN; Lee HJ; Jaya Lakshmi T; Yang S; Jung SH; Kim HJ; Lee JJ
Oncotarget; 2017 Apr; 8(16):27252-27262. PubMed ID: 28460478
[TBL] [Abstract][Full Text] [Related]
3. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.
Nguyen-Pham TN; Jung SH; Vo MC; Thanh-Tran HT; Lee YK; Lee HJ; Choi NR; Hoang MD; Kim HJ; Lee JJ
J Immunother; 2015 Oct; 38(8):330-9. PubMed ID: 26325377
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Pierceall WE; Amatangelo MD; Bahlis NJ; Siegel DS; Rahman A; Van Oekelen O; Neri P; Young M; Chung W; Serbina N; Parekh S; Agarwal A; Thakurta A
Clin Cancer Res; 2020 Nov; 26(22):5895-5902. PubMed ID: 32928795
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.
Vo MC; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Rhee JH; Lee JJ
Front Immunol; 2018; 9():1370. PubMed ID: 29967612
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.
Vo MC; Anh-NguyenThi T; Lee HJ; Nguyen-Pham TN; Jaya Lakshmi T; Jung SH; Kim HJ; Lee JJ
Exp Hematol; 2017 Feb; 46():48-55. PubMed ID: 27889516
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide enhances anti-myeloma cellular immunity.
Luptakova K; Rosenblatt J; Glotzbecker B; Mills H; Stroopinsky D; Kufe T; Vasir B; Arnason J; Tzachanis D; Zwicker JI; Joyce RM; Levine JD; Anderson KC; Kufe D; Avigan D
Cancer Immunol Immunother; 2013 Jan; 62(1):39-49. PubMed ID: 22733396
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Gandhi AK; Kang J; Capone L; Parton A; Wu L; Zhang LH; Mendy D; Lopez-Girona A; Tran T; Sapinoso L; Fang W; Xu S; Hampton G; Bartlett JB; Schafer P
Curr Cancer Drug Targets; 2010 Mar; 10(2):155-67. PubMed ID: 20088798
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions.
Falcón-Beas C; Tittarelli A; Mora-Bau G; Tempio F; Pérez C; Hevia D; Behrens C; Flores I; Falcón-Beas F; Garrido P; Ascui G; Pereda C; González FE; Salazar-Onfray F; López MN
Immunobiology; 2019 Sep; 224(5):697-705. PubMed ID: 31221438
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Sehgal K; Das R; Zhang L; Verma R; Deng Y; Kocoglu M; Vasquez J; Koduru S; Ren Y; Wang M; Couto S; Breider M; Hansel D; Seropian S; Cooper D; Thakurta A; Yao X; Dhodapkar KM; Dhodapkar MV
Blood; 2015 Jun; 125(26):4042-51. PubMed ID: 25869284
[TBL] [Abstract][Full Text] [Related]
17. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
[TBL] [Abstract][Full Text] [Related]
19. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF;
Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.
Fujiwara Y; Sun Y; Torphy RJ; He J; Yanaga K; Edil BH; Schulick RD; Zhu Y
Cancer Res; 2018 Dec; 78(23):6655-6665. PubMed ID: 30315115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
